Visual Abstract

ATOS, a prospective, 12-month observational study in 18 countries outside US and Western Europe, showed that initiation of Gla-300 in people with T2DM resulted in improved glycemic control with low rates of hypoglycemia and minimal weight change. Here we present the results from a subgroup analysis in participants with (N=581) or without (N=3841) a history of RI (~70% microalbuminuria, Table). Patients with RI were older (62.2±10.3 vs. 56.4±10.7 years), had a longer duration of T2DM (mean: 12.7±6.9 vs. 9.8±6.0 years) and more comorbidities than patients without RI. Baseline HbA1c was comparable between groups (9.3%). Physician-set individualized HbA1c (%) goals at baseline in the RI vs. non-RI groups were <7: 7.2 vs. 14.6%; 7-<7.5: 60.4 vs. 72.0%; 7.5-<8: 25.0 vs. 9.8%; ≥8: 7.4 vs. 3.6%. HbA1c target achievement at Month 6 was 27.5% (95% CI: 23.7-31.6) in RI group and 24.8% (95% CI: 23.4-26.3) in the non-RI group. There was no difference between groups in HbA1c reductions from baseline to Month 6 (-1.50 vs. -1.50%) and 12 (-1.84 vs. -1.88%). The reported hypoglycemia incidence was low although higher in the RI group (Table). Incidence of treatment-emergent adverse events was low in both RI (9.8%) and non-RI (5.9%) groups. Initiation of Gla-300 is effective with low risk of hypoglycemia in T2DM patients with and without RI.


A. Tirosh: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; Self; DreaMed Diabetes, Ltd. N. Khan: None. H. Vargas-uricoechea: Advisory Panel; Spouse/Partner; Sanofi. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Coudert: Employee; Self; Sanofi. V. Pilorget: Employee; Self; Sanofi. G. R. Galstyan: None.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at